Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone I Strasser

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
Cancers|June 19, 2024
Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Cancers|September 14, 2024
Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Gastroenterology|June 11, 2025
Defining Organ Failures in Patients with Cirrhosis: Consensus StatementsJasmohan S Bajaj, Debbie L Shawcross, Ashok Choudhury, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Hepatology Communications|April 1, 2026
The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensusAvik Majumdar, Jacinta Holmes, Stuart K Roberts, et al.
BMC Cancer|July 7, 2024
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC)Alan Wigg, Jonathan Tibballs, Richard Woodman, et al.
Hepatology Communications|September 25, 2022
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensusAshika D Maharaj, John Lubel, Eileen Lam, et al.
Open Forum Infectious Diseases|April 23, 2024
Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across AustraliaDao Sen Wang, Amy Phu, Kristen McKee, et al.
BMC Cancer|May 13, 2010
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinomaAndreas A Schnitzbauer, Carl Zuelke, Christian Graeb, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Cancers|June 19, 2024
Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Cancers|September 14, 2024
Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Gastroenterology|June 11, 2025
Defining Organ Failures in Patients with Cirrhosis: Consensus StatementsJasmohan S Bajaj, Debbie L Shawcross, Ashok Choudhury, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Hepatology Communications|April 1, 2026
The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensusAvik Majumdar, Jacinta Holmes, Stuart K Roberts, et al.
BMC Cancer|July 7, 2024
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC)Alan Wigg, Jonathan Tibballs, Richard Woodman, et al.
Hepatology Communications|September 25, 2022
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensusAshika D Maharaj, John Lubel, Eileen Lam, et al.
Open Forum Infectious Diseases|April 23, 2024
Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across AustraliaDao Sen Wang, Amy Phu, Kristen McKee, et al.
BMC Cancer|May 13, 2010
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinomaAndreas A Schnitzbauer, Carl Zuelke, Christian Graeb, et al.
Pageof 17